Eli Lilly will remove four insulin drugs with low or falling sales from the U.S. market, including its remaining animal-based insulins. Biosynthetic insulins began replacing animal insulins in 1983. Two percent of the 3.5 million insulin users in the U.S. depend on these products and will have until the end of the year to find replacements. The discontinued products make up a small percentage of the company's total insulin sales of more than $2 billion a year.
Published in Brief: